|Description||Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.|
GW501516 is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ. Phase 4.
Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...
Oleuropein is a polyphenol found in olive leaves and fruits. Oleuropein displays antioxidant, anti-ischemic and hypolipidemic activity. It has an antagonistic e...
NPC 15199 is an amino acid derivative. It is also one of the novel PPARγ ligands that can reduce osteoclasts differentiation through activating PPARγ.
Imiglitazar, also known as TAK-559，with hypoglycemic activity it is a non-thiazolidinedione dual peroxisome proliferator-activated receptor (PPAR) alpha and gam...
PPARγ is a ligand-activated nuclear receptor and was reported to plays a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation...
Indeglitazar is a peroxisome proliferator-activated receptor (PPAR) pan-agonist. Phase II clinical trials for Type 2 diabetes mellitus was discontinued.
BADGE is a PPARγ antagonist with selectivity over PPARδ and PPARα. It inhibits adipocyte differentiation, and induces apoptosis in cancer cells. BADGE also exhi...